Your browser doesn't support javascript.
loading
Dosing vs Assessment Intervals With Faricimab and Aflibercept.
Freund, K Bailey; Bijon, Jacques; Ramtohul, Prithvi.
Affiliation
  • Freund KB; Vitreous Retina Macula Consultants of New York, New York.
  • Bijon J; Department of Ophthalmology, New York University Grossman School of Medicine, New York.
  • Ramtohul P; Vitreous Retina Macula Consultants of New York, New York.
JAMA Ophthalmol ; 142(8): 697-698, 2024 Aug 01.
Article in En | MEDLINE | ID: mdl-38935351
This Viewpoint highlights the discrepancy between dosing and patient assessment schedules in clinical trials for 2 new intravitreal agents, faricimab, 6 mg, and aflibercept, 8 mg, to treat neovascular age-related macular degeneration.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Angiogenesis Inhibitors / Receptors, Vascular Endothelial Growth Factor / Vascular Endothelial Growth Factor A / Intravitreal Injections Limits: Humans / Male Language: En Journal: JAMA Ophthalmol Year: 2024 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Angiogenesis Inhibitors / Receptors, Vascular Endothelial Growth Factor / Vascular Endothelial Growth Factor A / Intravitreal Injections Limits: Humans / Male Language: En Journal: JAMA Ophthalmol Year: 2024 Document type: Article Country of publication: